Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Dawn Trueman"'
Autor:
James S. Scott, Darren Stead, Bernard Barlaam, Jason Breed, Rodrigo J. Carbajo, Elisabetta Chiarparin, Natalie Cureton, Paul R. J. Davey, David I. Fisher, Eric T. Gangl, Tyler Grebe, Ryan D. Greenwood, Sudhir Hande, Holia Hatoum-Mokdad, Samantha J. Hughes, Thomas A. Hunt, Tony Johnson, Stefan L. Kavanagh, Teresa C. M. Klinowska, Carrie J. B. Larner, Mandy Lawson, Andrew S. Lister, David Longmire, Stacey Marden, Thomas M. McGuire, Caroline McMillan, Lindsay McMurray, Christopher J. Morrow, J. Willem M. Nissink, Thomas A. Moss, Daniel H. O’Donovan, Radoslaw Polanski, Stephen Stokes, Kumar Thakur, Dawn Trueman, Caroline Truman, Michael J. Tucker, Haixia Wang, Nicky Whalley, Dedong Wu, Ye Wu, Bin Yang, Wenzhan Yang
Publikováno v:
Journal of Medicinal Chemistry. 66:2918-2945
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2ec7d4c4fb73ee3f4aed9c21a77b1bf
https://doi.org/10.1021/acs.jmedchem.2c01964
https://doi.org/10.1021/acs.jmedchem.2c01964
Autor:
Simon T. Barry, Elizabeth J. Pease, James E. Pilling, Nicola J. Curtis, Shenghua Wen, Maureen Hattersley, Vivien N. Jacobs, Jacqueline Caddy, Nicola Derbyshire, Kim Maratea, Rajesh Odedra, Emily Harris, Dawn Trueman, Paula Taylor, Susan Ashton, Nicolas Floc'h
Supplementary figues and tables: Figure S1. In vitro AZD1152-hQPA reduces proliferation and induces polyploidy across a panel of human AML cancer cell lines. Figure S2. AZD1152 has a modest effect on the growth of the HL-60 xenograft models in SCID m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c1a017c2051488311435f1b1d1a91b
https://doi.org/10.1158/1535-7163.22503183
https://doi.org/10.1158/1535-7163.22503183
Autor:
A. Nigel Brooks, Stephen R. Wedge, Susan E. Critchlow, Craig N. Robson, Simon T. Barry, Chris Womack, Luke Gaughan, Alfred Rabow, Robert H. Bradbury, Rhys D.O. Jones, Joanne Wilson, Marie Cumberbatch, Vivien N. Jacobs, Fadhel S. Shaheen, Elizabeth Mouchet, Dawn Trueman, Natalie C. Stratton, Nicola Broadbent, Sandra R. Brave, Tom P.J. Dunkley, Graeme E. Walker, David M. Robinson, Andrew G. Thomason, Sarah J. Ross, Sarah A. Loddick
PDF - 56KB, Supplementary methods detailing Relative peptide quantification by selected reaction monitoring (SRM)using mass spectrometry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d12f691841ae5003bde43d483fc498
https://doi.org/10.1158/1535-7163.22500958
https://doi.org/10.1158/1535-7163.22500958
Autor:
A. Nigel Brooks, Stephen R. Wedge, Susan E. Critchlow, Craig N. Robson, Simon T. Barry, Chris Womack, Luke Gaughan, Alfred Rabow, Robert H. Bradbury, Rhys D.O. Jones, Joanne Wilson, Marie Cumberbatch, Vivien N. Jacobs, Fadhel S. Shaheen, Elizabeth Mouchet, Dawn Trueman, Natalie C. Stratton, Nicola Broadbent, Sandra R. Brave, Tom P.J. Dunkley, Graeme E. Walker, David M. Robinson, Andrew G. Thomason, Sarah J. Ross, Sarah A. Loddick
PDF - 464KB, Supplementary Figure 1: Inhibition of AR transcripts with AZD3514 treated LNCaPs in steroid free media and the timecourse of AZD3514 effects in the presence and absence of DHT. Supplementary Figure 2: Effect of AZD3514 on growth of AR ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5d194c3a51c866f292b69afd928b73e
https://doi.org/10.1158/1535-7163.22500961
https://doi.org/10.1158/1535-7163.22500961
Autor:
A. Nigel Brooks, Stephen R. Wedge, Susan E. Critchlow, Craig N. Robson, Simon T. Barry, Chris Womack, Luke Gaughan, Alfred Rabow, Robert H. Bradbury, Rhys D.O. Jones, Joanne Wilson, Marie Cumberbatch, Vivien N. Jacobs, Fadhel S. Shaheen, Elizabeth Mouchet, Dawn Trueman, Natalie C. Stratton, Nicola Broadbent, Sandra R. Brave, Tom P.J. Dunkley, Graeme E. Walker, David M. Robinson, Andrew G. Thomason, Sarah J. Ross, Sarah A. Loddick
PDF - 71KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36cd40a1e742de8a4011274fdf37bb1e
https://doi.org/10.1158/1535-7163.22500964.v1
https://doi.org/10.1158/1535-7163.22500964.v1
Autor:
A. Nigel Brooks, Stephen R. Wedge, Susan E. Critchlow, Craig N. Robson, Simon T. Barry, Chris Womack, Luke Gaughan, Alfred Rabow, Robert H. Bradbury, Rhys D.O. Jones, Joanne Wilson, Marie Cumberbatch, Vivien N. Jacobs, Fadhel S. Shaheen, Elizabeth Mouchet, Dawn Trueman, Natalie C. Stratton, Nicola Broadbent, Sandra R. Brave, Tom P.J. Dunkley, Graeme E. Walker, David M. Robinson, Andrew G. Thomason, Sarah J. Ross, Sarah A. Loddick
PDF - 329KB, Supplementary Table 1: TSQ Vantage mass spectrometry instrument settings. Supplementary Table 2: 4000 QTRAP mass spectrometry instrument settings. Supplementary Table 3: The half-life of AR for the first 6 hours following treatment calcu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b48ad0925bc03fcf57e4609a27abf58
https://doi.org/10.1158/1535-7163.22500955
https://doi.org/10.1158/1535-7163.22500955
Autor:
Susan Ashton, Simon T. Barry, Rajesh Odedra, Nicola Curtis, Shenghua Wen, Nicolas Floc'h, Jacqueline Caddy, James Pilling, Paula Taylor, Dawn Trueman, Emily Harris, Maureen Hattersley, Vivien Jacobs, Nicola Derbyshire, Elizabeth Janet Pease, Kim Maratea
Publikováno v:
Molecular Cancer Therapeutics. 16:1031-1040
Barasertib (AZD1152), a highly potent and selective aurora kinase B inhibitor, gave promising clinical activity in elderly acute myeloid leukemia (AML) patients. However, clinical utility was limited by the requirement for a 7-day infusion. Here we a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb1fb84513231106f68c3f235cbfc599
https://doi.org/10.1158/1535-7163.mct-16-0580
https://doi.org/10.1158/1535-7163.mct-16-0580
Autor:
Bairu Zhang, Dawn Trueman, Azadeh Cheraghchi-Bashi-Astaneh, Pei Zhang, Jamie AstraZeneca R D Boston Scott, Christopher J. Morrow, Natalie Cureton, Mandy Lawson, Sladjana Gagrica, Jonathan Cairns, Oona Delpuech, Daniel Sutton, Teresa Klinowska, Gareth Maglennon, Michelle DuPont
Publikováno v:
Cancer Research. 80:4379-4379
Anti-hormonal therapy has been the mainstay treatment for estrogen receptor (ER) +ve breast cancer for >40 years. The selective ER degrader (SERD) fulvestrant has demonstrated clinical benefit over aromatase inhibitors and the selective ER modulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0a689ca296adee17c3cb2223cc75b3d
https://doi.org/10.1158/1538-7445.am2020-4379
https://doi.org/10.1158/1538-7445.am2020-4379
Autor:
Aaron Smith, Christopher J. Morrow, Natalie Cureton, Joanne Wilson, Dawn Trueman, Mandy Lawson, Teresa Klinowska, Eric Gangl, James S. Scott, Pablo Morentin Gutierrez
Publikováno v:
Cancer Research. 80:4369-4369
Objectives: The estrogen receptor alpha (ERα) is highly expressed in breast cancers and is a clinically validated target in oncology. AZD9833 is a novel potent oral selective estrogen receptor degrader (SERD) currently being tested in the clinic [SE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8808afc2bfb0d94fb4d7e64e02a27848
https://doi.org/10.1158/1538-7445.am2020-4369
https://doi.org/10.1158/1538-7445.am2020-4369
Autor:
Oona Delpuech, Azadeh Cheraghchi-Bashi-Astaneh, Mandy Lawson, Pei Zhang, Dawn Trueman, Bairu Zhang, Gareth Maglennon, Daniel Sutton, Christopher J. Morrow, Sladjana Gagrica, Natalie Cureton, Jonathan Cairns, Teresa Klinowska
Publikováno v:
Cancer Research. 80:P6-04
Anti-hormonal therapy has been the mainstay for the treatment of estrogen receptor (ER) positive breast cancer for over 40 years. The selective ER degrader (SERD) fulvestrant (Faslodex) has been shown to provide clinical benefit over aromatase inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15fa26d6895e2ae555cf79d61c86d514
https://doi.org/10.1158/1538-7445.sabcs19-p6-04-15
https://doi.org/10.1158/1538-7445.sabcs19-p6-04-15